Developer docs
API playgroundTry for free, no card

Search company profiles

Beyond Air

Full company profile

uuid0000p4z

Namestring
Beyond Air
Legal namestring
Beyond Air, Inc.
Websiteurl
beyondair.net
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Beyond Air, Inc. (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company headquartered in Garden City, NY that develops the LungFit family of inhaled nitric oxide (iNO) delivery systems. The LungFit platform is built on patented Ionizer/Plasma Pulse Technology that generates therapeutic nitric oxide on-demand from ambient room air, eliminating the need for the 45-pound high-pressure gas cylinders used by legacy iNO systems. The flagship commercial product, LungFit PH, received FDA Premarket Approval in 2022 for treating term and near-term neonates with persistent pulmonary hypertension of the newborn (PPHN) in hospital NICU settings at concentrations of ≤80 ppm.

The company's pipeline extends the platform into higher-concentration indications and alternate settings. LungFit PRO targets community-acquired viral pneumonia and bronchiolitis (80-400 ppm) in hospitals; LungFit GO is an at-home system targeting nontuberculous mycobacteria (NTM) lung infections and COPD exacerbations; and LungFit PH II is a second-generation, transport-ready device under FDA PMA supplement review. The NO2 Smart Filter is a recurring 12-hour consumable used across the product family. Beyond Air generates revenue through direct hospital sales in the U.S., supported by national Group Purchasing Organization agreements with Vizient, Premier, Inc., and a top 3 GPO (effective April 2026), plus international distribution partnerships spanning 40 countries. The company also operates two biotech subsidiaries: Beyond Cancer, Ltd. (ultra-high concentration nitric oxide for solid tumors) and NeuroNOS Ltd. (nNOS inhibitors for autism spectrum disorder, Phelan-McDermid syndrome, and glioblastoma). Cumulative funding raised is approximately $88.85 million across equity, debt, and royalty financings, with up to $32 million in Streeterville Capital financing secured in November 2025 to support commercial expansion and a stated path to profitability by year-end 2026.

Short descriptiontext

Beyond Air is a commercial-stage medical device company that develops the LungFit family of inhaled nitric oxide delivery systems, which generate iNO on-demand from ambient room air using patented Ionizer technology, primarily serving hospital NICUs treating neonates with PPHN.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersGarden City, United States
HQ citystring
Garden City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
inhaled nitric oxide therapy, neonatal respiratory care, tankless nitric oxide generator, medical device manufacturing, biopharmaceutical lung infection
Industry5 codes
PRIMARYHLAHAGAK
Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYIMAEACAF
Medical & Healthcare Gases
SECONDARYHLAKANAM
Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
NAICS code4 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
  • Pharmaceutical and Medicine Manufacturing3254
  • Industrial Gas Manufacturing32512
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Pharmaceutical Preparations2834
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Nitric Oxide Therapy Medical Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1LungFit PH Product Sales
TypeHardware Sales
Description

Commercial sales of FDA-approved LungFit PH nitric oxide delivery systems and associated consumables/accessories to hospitals. The company reports quarterly revenue with strong year-over-year growth (105% in Q3 FY2026).

globenewswire.com
2Royalty Funding
TypeLicensing Royalties
Description

$11.5 million royalty funding agreement based on commercial sales of LungFit PH product, providing non-dilutive capital based on product revenue.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Marketing or Sales, Personnel, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1LungFit
Description

Family of nitric oxide delivery systems including LungFit PH (hospital NICU), LungFit PRO (hospital setting for viral pneumonia), and LungFit GO (at-home treatment for NTM)

beyondair.net
+2 more records
Core offering1 text field

Beyond Air develops, manufactures, and commercializes the LungFit family of FDA-cleared medical devices that generate inhaled nitric oxide (iNO) on-demand from ambient room air using patented Ionizer technology, eliminating the need for traditional high-pressure gas cylinders. The company's commercial product, LungFit PH, is sold to hospital neonatal intensive care units (NICUs) for treating persistent pulmonary hypertension of the newborn (PPHN), with pipeline systems (LungFit PRO, LungFit GO, LungFit PH II) targeting broader respiratory and infectious disease applications, plus biotech subsidiary programs in oncology and central nervous system therapeutics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Revenue growth of 105% year-over-year to $2.2 million in Q3 FY2026
+2 more records
Product overview1 text field

Beyond Air is a commercial-stage medical device and biopharmaceutical company offering the LungFit family of products - a platform of tankless, on-demand nitric oxide generation systems that produce inhaled nitric oxide (iNO) directly from ambient air using patented Ionizer/Plasma Pulse Technology. The product family includes LungFit PH (FDA-approved for neonatal PPHN in hospital NICU settings, low-concentration ≤80 ppm), LungFit PRO (for hospital-based treatment of viral pneumonia and bronchiolitis, high-concentration 80-400 ppm), and LungFit GO (for at-home NTM and COPD treatment, high-concentration 80-400 ppm). The company also operates two biotech subsidiaries: NeuroNOS (developing nNOS inhibitors for autism, Phelan-McDermid syndrome, and Alzheimer's) and BeyondCancer (developing ultra-high concentration nitric oxide therapy for solid tumor cancer treatment). The company transitioned to a commercial-stage company following FDA approval of LungFit PH in 2022 and is pursuing international expansion with recent approvals in Australia and Europe.

Product and service5 records
1LungFit PH
CategoryCore Product
Description

FDA-approved hospital NICU device that generates low-concentration inhaled nitric oxide (iNO ≤80 ppm) from room air using patented Ionizer technology to treat term and near-term neonates with hypoxic respiratory failure / persistent pulmonary hypertension of the newborn (PPHN).

2LungFit PRO
CategoryPipeline Product
Description

Hospital-based system that generates high-concentration inhaled nitric oxide (80-400 ppm) using patented Ionizer technology for treating community-acquired viral pneumonia (including COVID-19) and bronchiolitis; investigational device limited by federal law to investigational use.

3LungFit GO
CategoryPipeline Product
Description

At-home treatment system that generates high-concentration inhaled nitric oxide (80-400 ppm) for treating nontuberculous mycobacteria (NTM) lung infections and persistent lung infections in COPD patients; investigational device limited by federal law to investigational use.

4LungFit PH II
CategoryProduct Upgrade / Next-Generation Device
Description

Second-generation LungFit PH system, approximately half the weight of the first generation, with simplified operations, longer service intervals, air and ground transport compatibility, and an automated backup system; PMA supplement currently under FDA review.

5NO2 Smart Filter
CategoryAccessory / Consumable
Description

Disposable filter component used across the LungFit product family that reduces risk of NO2 exposure to patient and clinician, with integrated auto-purging; filter change required every 12 hours regardless of dose or flow.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Top 3 National Group Purchasing Organization
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-01
Description

National group purchasing agreement providing access to approximately 2,000 additional U.S. hospitals and health systems for LungFit PH inhaled nitric oxide therapy. Building on existing GPO relationships with Vizient and Premier, Inc.

finance.yahoo.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-01
Description

Existing GPO relationship providing access to Vizient-member hospitals for LungFit PH purchasing.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-01
Description

Existing GPO relationship providing access to Premier-member hospitals for LungFit PH purchasing.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Binding agreement for XTL to acquire 85% of Beyond Air's NeuroNOS subsidiary for 19.9% of XTL share capital, $1 million cash, and up to $32.5 million in milestone payments. Beyond Air retains 19.99% stake post-transaction. NeuroNOS developing treatments for Autism Spectrum Disorder and neuro-oncology.

5Getz Healthcare
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-17
Description

Regional commercial partner for 10 Asian countries (excluding Japan), recognized as leading distributor of medical equipment, devices, and consumables in Asia Pacific. Partner for Australia market launch through TGA authorization.

globenewswire.com
6Vanderbilt University Medical Center
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-07-26
Description

Clinical partnership for high-dose inhaled nitric oxide research using LungFit PRO device in randomized clinical study for viral pneumonia (COVID-19).

nature.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Investor relations support provided by LifeSci Advisors (Corey Davis, New York office). Manages investor communications and relations.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Vapotherm develops high-flow nasal cannula respiratory therapy systems for neonates and adults in respiratory distress. Comparable as a respiratory gas-delivery device vendor targeting similar NICU and hospital respiratory customers, though using a different gas-delivery mechanism.

TypeBroad incumbent
Description

Linde is the global industrial gas incumbent and supplies medical-grade nitric oxide and other gases to hospitals, including through cylinder distribution. Comparable because Beyond Air's LungFit directly displaces the cylinder supply chain that Linde and its peers (Air Liquide, Air Products) operate.

TypeDirect peer
Description

Mallinckrodt markets INOmax, the incumbent cylinder-based inhaled nitric oxide delivery system for neonatal respiratory failure. Directly comparable as the established iNO therapy provider to the same hospital NICU customer base that Beyond Air's LungFit PH targets.

TypeBroad incumbent
Description

ResMed is a leading manufacturer of respiratory care devices for sleep apnea, COPD, and hospital ventilation. Comparable as a respiratory device incumbent whose hospital and home-care sales channels overlap with the customer base Beyond Air is building for LungFit PH and LungFit GO.

TypeOthers
Description

Masimo develops patient monitoring and pulse oximetry technologies widely used in NICU and ICU settings alongside inhaled nitric oxide therapy. Comparable as a NICU-adjacent technology supplier whose installed base overlaps with the clinical workflow into which LungFit systems integrate.

6Bellerophon Therapeutics
TypeEmerging player
Description

Bellerophon develops INOpulse, a pulsatile nitric oxide delivery system targeting pulmonary hypertension in COPD and other indications. Directly comparable as a competing iNO platform pursuing adjacent respiratory indications, though with a different delivery mechanism.

TypeBroad incumbent
Description

Getinge (including Maquet) manufactures ventilators and respiratory care equipment for hospital ICUs and NICUs. Comparable as an established supplier of respiratory care capital equipment to the same hospital procurement channels that Beyond Air accesses via GPOs.

TypeEmerging player
Description

Inogen develops portable oxygen concentrators for home and ambulatory use. Comparable as a respiratory home-care device company pursuing a similar 'tankless / on-demand' displacement thesis versus traditional cylinder delivery for chronic respiratory patients.

9Drägerwerk
TypeBroad incumbent
Description

Dräger is a broad medical technology incumbent with ventilator and anesthesia gas delivery systems used in NICUs. Comparable as a supplier of respiratory and gas-delivery equipment to the same hospital customer base, though its portfolio spans far beyond nitric oxide.

TypeBroad incumbent
Description

Air Liquide manufactures and distributes medical and industrial gases including nitric oxide cylinders to hospitals worldwide. Comparable as a supplier of the cylinder-based iNO delivery infrastructure that Beyond Air's tankless platform targets to displace.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Beyond Air

Nitric Oxide Therapy Medical Devicesbeyondair.net

Beyond Air is a commercial-stage medical device company that develops the LungFit family of inhaled nitric oxide delivery systems, which generate iNO on-demand from ambient room air using patented Ionizer technology, primarily serving hospital NICUs treating neonates with PPHN.

What Beyond Air does

Beyond Air, Inc. (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company headquartered in Garden City, NY that develops the LungFit family of inhaled nitric oxide (iNO) delivery systems. The LungFit platform is built on patented Ionizer/Plasma Pulse Technology that generates therapeutic nitric oxide on-demand from ambient room air, eliminating the need for the 45-pound high-pressure gas cylinders used by legacy iNO systems. The flagship commercial product, LungFit PH, received FDA Premarket Approval in 2022 for treating term and near-term neonates with persistent pulmonary hypertension of the newborn (PPHN) in hospital NICU settings at concentrations of ≤80 ppm.

The company's pipeline extends the platform into higher-concentration indications and alternate settings. LungFit PRO targets community-acquired viral pneumonia and bronchiolitis (80-400 ppm) in hospitals; LungFit GO is an at-home system targeting nontuberculous mycobacteria (NTM) lung infections and COPD exacerbations; and LungFit PH II is a second-generation, transport-ready device under FDA PMA supplement review. The NO2 Smart Filter is a recurring 12-hour consumable used across the product family. Beyond Air generates revenue through direct hospital sales in the U.S., supported by national Group Purchasing Organization agreements with Vizient, Premier, Inc., and a top 3 GPO (effective April 2026), plus international distribution partnerships spanning 40 countries. The company also operates two biotech subsidiaries: Beyond Cancer, Ltd. (ultra-high concentration nitric oxide for solid tumors) and NeuroNOS Ltd. (nNOS inhibitors for autism spectrum disorder, Phelan-McDermid syndrome, and glioblastoma). Cumulative funding raised is approximately $88.85 million across equity, debt, and royalty financings, with up to $32 million in Streeterville Capital financing secured in November 2025 to support commercial expansion and a stated path to profitability by year-end 2026.

Beyond Air firmographics

Firmographics
Name
Beyond Air
Legal name
Beyond Air, Inc.
Website
https://beyondair.net
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
Beyond Air is a commercial-stage medical device company that develops the LungFit family of inhaled nitric oxide delivery systems, which generate iNO on-demand from ambient room air using patented Ionizer technology, primarily serving hospital NICUs treating neonates with PPHN.
Ownership category
akta.pro rank

Beyond Air industry classification

Industry
Product category
Nitric Oxide Therapy Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Pharmaceutical and Medicine Manufacturing (3254), Industrial Gas Manufacturing (32512)
SIC
Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAHAGAK
Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYIMAEACAF
Medical & Healthcare Gases
SECONDARYHLAKANAM
Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals

Keywords

  • Inhaled nitric oxide therapy
  • Neonatal respiratory care
  • Tankless nitric oxide generator
  • Medical device manufacturing
  • Biopharmaceutical lung infection

Where Beyond Air is headquartered

Location

Headquarters

HQ city
Garden City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Beyond Air business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Marketing or Sales, Personnel, Others

Revenue model

  1. LungFit PH Product Sales: Commercial sales of FDA-approved LungFit PH nitric oxide delivery systems and associated consumables/accessories to hospitals. The company reports quarterly revenue with strong year-over-year growth (105% in Q3 FY2026).
  2. Royalty Funding: $11.5 million royalty funding agreement based on commercial sales of LungFit PH product, providing non-dilutive capital based on product revenue.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Beyond Air product offering

Product offering

Core offering

Beyond Air develops, manufactures, and commercializes the LungFit family of FDA-cleared medical devices that generate inhaled nitric oxide (iNO) on-demand from ambient room air using patented Ionizer technology, eliminating the need for traditional high-pressure gas cylinders. The company's commercial product, LungFit PH, is sold to hospital neonatal intensive care units (NICUs) for treating persistent pulmonary hypertension of the newborn (PPHN), with pipeline systems (LungFit PRO, LungFit GO, LungFit PH II) targeting broader respiratory and infectious disease applications, plus biotech subsidiary programs in oncology and central nervous system therapeutics.

Product overview

Beyond Air is a commercial-stage medical device and biopharmaceutical company offering the LungFit family of products - a platform of tankless, on-demand nitric oxide generation systems that produce inhaled nitric oxide (iNO) directly from ambient air using patented Ionizer/Plasma Pulse Technology. The product family includes LungFit PH (FDA-approved for neonatal PPHN in hospital NICU settings, low-concentration ≤80 ppm), LungFit PRO (for hospital-based treatment of viral pneumonia and bronchiolitis, high-concentration 80-400 ppm), and LungFit GO (for at-home NTM and COPD treatment, high-concentration 80-400 ppm). The company also operates two biotech subsidiaries: NeuroNOS (developing nNOS inhibitors for autism, Phelan-McDermid syndrome, and Alzheimer's) and BeyondCancer (developing ultra-high concentration nitric oxide therapy for solid tumor cancer treatment). The company transitioned to a commercial-stage company following FDA approval of LungFit PH in 2022 and is pursuing international expansion with recent approvals in Australia and Europe.

Differentiator

Problem solved

Functional benefit

Brands

  • LungFit: Family of nitric oxide delivery systems including LungFit PH (hospital NICU), LungFit PRO (hospital setting for viral pneumonia), and LungFit GO (at-home treatment for NTM)
  • Beyond Cancer
  • NeuroNOS

Products and services

  • LungFit PH FDA-approved hospital NICU device that generates low-concentration inhaled nitric oxide (iNO ≤80 ppm) from room air using patented Ionizer technology to treat term and near-term neonates with hypoxic respiratory failure / persistent pulmonary hypertension of the newborn (PPHN).
  • LungFit PRO Hospital-based system that generates high-concentration inhaled nitric oxide (80-400 ppm) using patented Ionizer technology for treating community-acquired viral pneumonia (including COVID-19) and bronchiolitis; investigational device limited by federal law to investigational use.
  • LungFit GO At-home treatment system that generates high-concentration inhaled nitric oxide (80-400 ppm) for treating nontuberculous mycobacteria (NTM) lung infections and persistent lung infections in COPD patients; investigational device limited by federal law to investigational use.
  • LungFit PH II Second-generation LungFit PH system, approximately half the weight of the first generation, with simplified operations, longer service intervals, air and ground transport compatibility, and an automated backup system; PMA supplement currently under FDA review.
  • NO2 Smart Filter Disposable filter component used across the LungFit product family that reduces risk of NO2 exposure to patient and clinician, with integrated auto-purging; filter change required every 12 hours regardless of dose or flow.

Quantifiable outcome

  • Revenue growth of 105% year-over-year to $2.2 million in Q3 FY2026
  • +2 more outcomes

Companies that use Beyond Air

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Beyond Air technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Beyond Air partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, major and minor.

  • Top 3 National Group Purchasing OrganizationcoreChannel Partner/ Reseller/ Distributor · 1 April 2026National group purchasing agreement providing access to approximately 2,000 additional U.S. hospitals and health systems for LungFit PH inhaled nitric oxide therapy. Building on existing GPO relationships with Vizient and Premier, Inc.
  • VizientcoreChannel Partner/ Reseller/ Distributor · 1 April 2026Existing GPO relationship providing access to Vizient-member hospitals for LungFit PH purchasing.
  • Premier, Inc.coreChannel Partner/ Reseller/ Distributor · 1 April 2026Existing GPO relationship providing access to Premier-member hospitals for LungFit PH purchasing.
  • XTL Biopharmaceuticals Ltd.majorStrategic or Co-development Partner · 13 January 2026Binding agreement for XTL to acquire 85% of Beyond Air's NeuroNOS subsidiary for 19.9% of XTL share capital, $1 million cash, and up to $32.5 million in milestone payments. Beyond Air retains 19.99% stake post-transaction. NeuroNOS developing treatments for Autism Spectrum Disorder and neuro-oncology.
  • Getz HealthcarecoreChannel Partner/ Reseller/ Distributor · 17 December 2025Regional commercial partner for 10 Asian countries (excluding Japan), recognized as leading distributor of medical equipment, devices, and consumables in Asia Pacific. Partner for Australia market launch through TGA authorization.
  • Vanderbilt University Medical CenterminorStrategic or Co-development Partner · 26 July 2024Clinical partnership for high-dose inhaled nitric oxide research using LungFit PRO device in randomized clinical study for viral pneumonia (COVID-19).
  • LifeSci AdvisorsminorGTM or Marketing PartnerInvestor relations support provided by LifeSci Advisors (Corey Davis, New York office). Manages investor communications and relations.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Beyond Air competitors and assessment

Company assessment

Direct peers

  • Vapotherm: Vapotherm develops high-flow nasal cannula respiratory therapy systems for neonates and adults in respiratory distress. Comparable as a respiratory gas-delivery device vendor targeting similar NICU and hospital respiratory customers, though using a different gas-delivery mechanism.
  • Mallinckrodt plc: Mallinckrodt markets INOmax, the incumbent cylinder-based inhaled nitric oxide delivery system for neonatal respiratory failure. Directly comparable as the established iNO therapy provider to the same hospital NICU customer base that Beyond Air's LungFit PH targets.

Broad incumbents

  • Linde plc: Linde is the global industrial gas incumbent and supplies medical-grade nitric oxide and other gases to hospitals, including through cylinder distribution. Comparable because Beyond Air's LungFit directly displaces the cylinder supply chain that Linde and its peers (Air Liquide, Air Products) operate.
  • ResMed: ResMed is a leading manufacturer of respiratory care devices for sleep apnea, COPD, and hospital ventilation. Comparable as a respiratory device incumbent whose hospital and home-care sales channels overlap with the customer base Beyond Air is building for LungFit PH and LungFit GO.
  • Getinge (Maquet): Getinge (including Maquet) manufactures ventilators and respiratory care equipment for hospital ICUs and NICUs. Comparable as an established supplier of respiratory care capital equipment to the same hospital procurement channels that Beyond Air accesses via GPOs.
  • Drägerwerk: Dräger is a broad medical technology incumbent with ventilator and anesthesia gas delivery systems used in NICUs. Comparable as a supplier of respiratory and gas-delivery equipment to the same hospital customer base, though its portfolio spans far beyond nitric oxide.
  • Air Liquide: Air Liquide manufactures and distributes medical and industrial gases including nitric oxide cylinders to hospitals worldwide. Comparable as a supplier of the cylinder-based iNO delivery infrastructure that Beyond Air's tankless platform targets to displace.

Others

  • Masimo: Masimo develops patient monitoring and pulse oximetry technologies widely used in NICU and ICU settings alongside inhaled nitric oxide therapy. Comparable as a NICU-adjacent technology supplier whose installed base overlaps with the clinical workflow into which LungFit systems integrate.

Emerging players

  • Bellerophon Therapeutics: Bellerophon develops INOpulse, a pulsatile nitric oxide delivery system targeting pulmonary hypertension in COPD and other indications. Directly comparable as a competing iNO platform pursuing adjacent respiratory indications, though with a different delivery mechanism.
  • Inogen: Inogen develops portable oxygen concentrators for home and ambulatory use. Comparable as a respiratory home-care device company pursuing a similar 'tankless / on-demand' displacement thesis versus traditional cylinder delivery for chronic respiratory patients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Beyond Air social profiles

Digital presence

Beyond Air compliance and trust

Trust signal

Compliance3 records

Beyond Air financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Beyond Air leadership team

Management profile

Number of profiles

Profiles9 records

Beyond Air subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Beyond Air funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Beyond Air M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beyond Air

What does Beyond Air do?

Beyond Air develops, manufactures, and commercializes the LungFit family of FDA-cleared medical devices that generate inhaled nitric oxide (iNO) on-demand from ambient room air using patented Ionizer technology, eliminating the need for traditional high-pressure gas cylinders. The company's commercial product, LungFit PH, is sold to hospital neonatal intensive care units (NICUs) for treating persistent pulmonary hypertension of the newborn (PPHN), with pipeline systems (LungFit PRO, LungFit GO, LungFit PH II) targeting broader respiratory and infectious disease applications, plus biotech subsidiary programs in oncology and central nervous system therapeutics.

Is Beyond Air a public or private company?

Beyond Air is a public company. It is classified as public and is currently operating.

When was Beyond Air founded?

Beyond Air was founded in 2011. It employs 51 to 100 people.

Where is Beyond Air based?

Beyond Air is headquartered in Garden City, United States, in the North America region.

How does Beyond Air make money?

Two revenue lines are on record. LungFit PH Product Sales are the primary driver. The others are royalty Funding.

Who are Beyond Air's main competitors?

Direct peers on record are Vapotherm and Mallinckrodt plc. Broad incumbents are Linde plc, ResMed, Getinge (Maquet), Drägerwerk and Air Liquide. Masimo is listed as an others. Emerging players are Bellerophon Therapeutics and Inogen.

Does Beyond Air have an API?

No public API is recorded for Beyond Air.

What industry is Beyond Air in?

Beyond Air's product category is Nitric Oxide Therapy Medical Devices. Its primary akta.pro industry code is HLAHAGAK, Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers), with a secondary code of IMAEACAF, Medical & Healthcare Gases. Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingNational Advertising Division Will Refer Beyond Air to Regulatory Authorities for Declining to Participate in Self-Regulatory ProcessBBB National Programs' National Advertising Division will refer Beyond Air, Inc. to regulatory authorities after Vero Biotech Inc. challenged its LungFit PH system's claims. The challenge, a Fast-Track SWIFT case, concerned logistical dependencies and burdens compared to Vero's GENOSYL system. Beyond Air declined to participate in the self-regulatory process.Seeking AlphaBeyond Air, Inc. (XAIR) Q2 2027 Earnings Call TranscriptBeyond Air's Q2 2027 earnings call on November 11, 2026, featured CEO Robert Goodman and CFO Daniel Moorhead discussing operational highlights and financial results for the quarter ended September 30, 2026. The call included forward-looking statements about future expectations, plans, and prospects, with a caution that actual results may differ materially.Quiver QuantitativeBEYOND AIR ($XAIR) Releases Q2 2027 Earnings | XAIR Stock NewsBEYOND AIR reported Q2 2027 earnings of -$3.76 per share, missing estimates by $1.18, and revenue of $2.32 million, missing by $1.25 million. The stock fell 16.65% after market close. Insiders made six purchases in six months, while 14 institutional investors added shares and 15 reduced positions.BenzingaBeyond Air Q2 2027 Earnings Call Transcript - Beyond Air (NASDAQ:XAIR)Beyond Air reported record Q3 2026 revenue of $2.3 million, up 28% year-over-year, with a net loss of $7.8 million. The company reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16-18 million, pending FDA approval for its second-generation LungFit PH system.TradingViewBeyond Air Q2 2027 Earnings Call Is LiveBeyond Air's Q2 2027 earnings call is live, with executives discussing financial results and answering analyst questions. Management commentary on demand, margins, or capital spending may move markets.American Banking and Market NewsBeyond Air (XAIR) Projected to Release Earnings on WednesdayBeyond Air is projected to report Q2 2027 earnings on Wednesday, November 11th, after market close. Analysts expect EPS of ($3.31) and revenue of $2.16 million, following a prior Q2 2026 loss of $11.00 EPS and $1.77 million revenue. The company's stock opened at $2.29, with an average analyst target of $105.00.American Banking and Market NewsComparing Orchestra BioMed (NASDAQ:OBIO) & Beyond Air (NASDAQ:XAIR)Orchestra BioMed and Beyond Air are compared on dividends, valuation, profitability, earnings, institutional ownership, and analyst recommendations. Beyond Air has a higher consensus target price ($105 vs $13.17) and a larger upside (4,694.52% vs 126.23%), but Orchestra BioMed beats on 10 of 13 factors.Seeking AlphaBeyond Air expects revenue of $2.3M for quarter ended September 30 (XAIR:NASDAQ)Beyond Air expects Q3 2026 revenue of $2.3M, a 27% year-on-year rise, driven by its LungFit PH rollout. The company reaffirmed its 2026 revenue guidance of $8M and 2027 guidance of $16M-$18M, pending FDA approval for the second-generation system.Quiver QuantitativeBeyond Air Preannounces $2.3 Million Third-Quarter Revenue | XAIR Stock NewsBeyond Air reported preliminary Q3 2026 revenue of about $2.3 million, its highest quarterly result, up 30% from the prior quarter. The company reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16–18 million, excluding second-generation LungFit PH revenue pending FDA approval.American Banking and Market NewsBeyond Air (NASDAQ:XAIR) and Align Technology (NASDAQ:ALGN) Financial AnalysisAlign Technology and Beyond Air are compared on profitability, institutional ownership, risk, and analyst recommendations. Align has higher revenue and earnings, but Beyond Air shows a much higher potential upside from its price target. Align beats Beyond Air on 13 of 15 factors.